Trial Profile

A Phase II/III efficacy trial of ASN120290 for progressive supranuclear palsy (PSP)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FNP 223 (Primary)
Indications Progressive supranuclear palsy
Focus Therapeutic Use

Most Recent Events

01 Apr 2022 According to an Asceneuron media release, the company currently has an open investigational new drug (IND) application with the US Food and Drug Association (FDA) for a Phase 2/3 study to evaluate ASN90 in progressive supranuclear palsy (PSP), an orphan indication.
24 Jan 2019 New trial record
17 Jan 2019 According to an Asceneuron media release, this trial is planned for later this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com